Auburn U, Gen9, Autodesk Collaborate on Synthetic Oncolytic Virus to Treat Cancer in Dogs | GenomeWeb

NEW YORK (GenomeWeb) – A collaboration between a veterinary oncologist, synthetic DNA manufacturer Gen9, and design software firm Autodesk claims to have created the largest synthetic viral genome to date, which will be used in clinical trials to treat cancer in dogs using oncolytic viruses.

The synthetic canine adenovirus Type 2 (CAV-2) genome measures between 32 and 33 kilobases, a record, based on a recent literature search, Gen9 VP of Research and Development Devin Leake told GenomeWeb. He noted that several synthetized bacterial genomes have been larger.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.